In this regard, CLL that at diagnosis presented del17p13 without TP53 mutations displayed a significantly longer time to chemorefractoriness than CLL with TP53 mutations already at diagnosis [42]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.